Patents by Inventor James Sikorski

James Sikorski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9944597
    Abstract: The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the ?-III isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: April 17, 2018
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, VIRGINIA COMMONWEALTH UNIVERSITY, UNIVERSITY OF RICHMOND
    Inventors: Glen E. Kellogg, Chenxiao Da, Ashutosh Tripathi, John T. Gupton, Nakul Telang, James A. Sikorski, Susan L. Mooberry, Cristina Rohena
  • Publication number: 20160297757
    Abstract: The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the ?-III isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.
    Type: Application
    Filed: September 16, 2014
    Publication date: October 13, 2016
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY STEM
    Inventors: Glen E. KELLOGG, Chenxiao DA, Ashutosh TRIPATHI, John T. GUPTON, Nankul TELANG, James A. SIKORSKI, Susan L. MOOBERRY, Cristina ROHENA
  • Patent number: 9352743
    Abstract: A hydraulic hybrid system for implementation in a machine. The system includes a hydraulic system, an energy source, an output, and a transmission. The hydraulic system includes a primary hydraulic pump/motor (primary motor) that is hydraulically coupled to a reservoir and a variable-volume accumulator assembly. The primary motor is configured to charge an accumulator of the variable-volume accumulator assembly with a working fluid when mechanically driven. The storage volume of variable-volume accumulator assembly varies based on a kinetic output condition of the machine. The energy source is configured to produce primary kinetic energy. The output is configured to receive at least a first portion of the primary kinetic energy. The transmission is coupled between the energy source and the output and selectively coupled to the primary motor. The transmission is configured to mechanically drive the primary motor using a second portion of the primary kinetic energy.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 31, 2016
    Assignee: STORED ENERGY SOLUTIONS INC.
    Inventors: Robert Dane Davis, Robert James Sikorski
  • Publication number: 20160047397
    Abstract: An example embodiment includes a hydraulic hybrid system. The hydraulic hybrid system includes a hydraulic system, an energy source configured to produce primary kinetic energy, an output configured to receive at least a first portion of the primary kinetic energy, and a transmission coupled between the energy source and the output and selectively coupled to the hydraulic system. The hydraulic system includes a reservoir, a sequenced accumulator assembly, and a hydraulic pump/motor that is hydraulically coupled to the reservoir and the sequenced accumulator assembly and configured to charge the sequenced accumulator assembly when mechanically driven. The sequenced accumulator assembly includes two or more accumulators, one or more sequence valves, and one or more check valves. The sequenced accumulator assembly is configured to store varying amounts of potential hydraulic energy by introducing and removing one or more of the accumulators from operation.
    Type: Application
    Filed: October 23, 2015
    Publication date: February 18, 2016
    Inventors: Robert James Sikorski, Ren Levi Copeland
  • Publication number: 20140274522
    Abstract: A hydraulic hybrid system for implementation in a machine. The system includes a hydraulic system, an energy source, an output, and a transmission. The hydraulic system includes a primary hydraulic pump/motor (primary motor) that is hydraulically coupled to a reservoir and a variable-volume accumulator assembly. The primary motor is configured to charge an accumulator of the variable-volume accumulator assembly with a working fluid when mechanically driven. The storage volume of variable-volume accumulator assembly varies based on a kinetic output condition of the machine. The energy source is configured to produce primary kinetic energy. The output is configured to receive at least a first portion of the primary kinetic energy. The transmission is coupled between the energy source and the output and selectively coupled to the primary motor. The transmission is configured to mechanically drive the primary motor using a second portion of the primary kinetic energy.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: Stored Energy Solutions Inc.
    Inventors: Robert Dane Davis, Robert James Sikorski
  • Patent number: 7897776
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: March 1, 2011
    Assignee: Salutria Pharmaceuticals LLC
    Inventors: M. David Weingarten, Charles Q. Meng, James A. Sikorski, Raymond Ng, Wei Zhang
  • Publication number: 20090270454
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.
    Type: Application
    Filed: April 23, 2008
    Publication date: October 29, 2009
    Inventors: M. David Weingarten, Charles Q. Meng, James A. Sikorski, Raymond Ng, Wei Zhang
  • Publication number: 20090156685
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Application
    Filed: January 29, 2008
    Publication date: June 18, 2009
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Publication number: 20080176842
    Abstract: Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibiting compounds of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein.
    Type: Application
    Filed: November 14, 2007
    Publication date: July 24, 2008
    Applicant: G.D. SEARLE LLC
    Inventors: John N. Freskos, Daniel P. Getman, John J. Talley, James A. Sikorski
  • Publication number: 20080118969
    Abstract: Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
    Type: Application
    Filed: January 29, 2008
    Publication date: May 22, 2008
    Applicant: G.D. Searle LLC
    Inventors: Daniel Getman, Gary DeCrescenzo, John Freskos, Michael Vazquez, James Sikorski, Balekudru Devadas, Srinivasan Nagarajan, David Brown, Joseph McDonald
  • Patent number: 7339078
    Abstract: Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compositions, and methods for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: March 4, 2008
    Assignee: G.D. Searle LLC
    Inventors: Daniel P Getman, Gary A DeCrescenzo, John N Freskos, Michael L Vazquez, James A Sikorski, Balekudru Devadas, Srinivasan Raj Nagarajan, David L Brown, Joseph J McDonald
  • Publication number: 20080009642
    Abstract: A probucol or a probucol derivative can be efficiently converted to a monoester or monoether of probucol by reacting the free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol molecule but which maintains the two free hydroxyl groups) with a Grignard reagent or a lithium reagent that produces a magnesium bromide or lithium salt of probucol or the probucol derivative. The probucol compound anion anion is then reacted with an ester or ether forming compound.
    Type: Application
    Filed: September 13, 2007
    Publication date: January 10, 2008
    Inventors: James Sikorski, M. Weingarten
  • Patent number: 7297793
    Abstract: Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibiting compounds of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: November 20, 2007
    Assignee: G.D. Searle, LLC
    Inventors: John N. Freskos, Daniel P. Getman, John J. Talley, James A. Sikorski
  • Patent number: 7273948
    Abstract: A probucol or a probucol derivative can be efficiently converted to a monoester or monoether of probucol by reacting the free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol molecule but which maintains the two free hydroxyl groups) with a Grignard reagent or a lithium reagent that produces a magnesium bromide or lithium salt of probucol or the probucol derivative. The probucol compound anion anion is then reacted with an ester or ether forming compound.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: September 25, 2007
    Assignee: AtheroGenics, Inc.
    Inventors: M. David Weingarten, James A. Sikorski
  • Publication number: 20070219274
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Application
    Filed: March 29, 2007
    Publication date: September 20, 2007
    Inventors: James Sikorski, Richard Durley, Margaret Grapperhaus, Mark Massa, Emily Reinhard, Yvette Fobian, Michael Tollefson, Lijuan Wang, Brian Hickory, Monica Norton, William Vernier, Deborah Mischke, Michelle Promo, Ashton Hamme, Dale Spangler, Melvin Rueppel
  • Publication number: 20070203246
    Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.
    Type: Application
    Filed: May 1, 2007
    Publication date: August 30, 2007
    Inventors: Bradley Keller, James Sikorski, Kevin Glenn, Daniel Connolly, Mark Smith
  • Patent number: 7253211
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: August 7, 2007
    Assignee: Pfizer Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Publication number: 20070093453
    Abstract: The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
    Type: Application
    Filed: December 15, 2006
    Publication date: April 26, 2007
    Applicant: AtheroGenics, Inc.
    Inventors: Kimberly Worsencroft, Liming Ni, Zhihong Ye, Charles Meng, M. Weingarten, Jacob Simpson, James Sikorski
  • Patent number: 7202247
    Abstract: The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: April 10, 2007
    Assignee: AtheroGenics, Inc.
    Inventors: James A. Sikorski, Charles Q. Meng, M. David Weingarten
  • Patent number: 7183317
    Abstract: It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: February 27, 2007
    Assignee: Atherogenics, Inc.
    Inventors: James A. Sikorski, Jayraz Luchoomun, Charles Q. Meng, Uday Saxena